Migraine Drugs Market, By Treatment (Abortive or Acute and Prophylactic or Preventive), By Route of Administration (Oral, Injectable, and Others (Nasal Spray and Transdermal Patch)), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

The markets for migraine medications are examined in detail in the following important regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Market data from significant countries within each region is examined to gain a macro-level picture of the migraine medicine industry. The migraine medication market is anticipated to generate the largest revenue share in North America in 2018; other regions will follow. This is linked to the increased prevalence of migraine in the nations of the North American continent. For example, the National Institutes of Health (NIH) reported that 37 million Americans, or 12% of the population, suffered migraines in 2017. Both adults and children suffer from these incapacitating headaches, and about 18% of women report having migraines, which are three times more common in women than in men. The Asia Pacific market is growing in the global market for migraine medications. This is because of rising healthcare costs, a sizable underserved patient population, inexpensive drug production, and rising disease awareness in the region's nations.